FdaApplication
BLA 020280
Identifiers
- fda_app_no: BLA020280
Properties
| Property | Value |
|---|---|
| applicant_name | Pharmacia & Upjohn Company LLC |
| application_type | BLA |
| approval_date | 1995-08-24 |
Revenue by product
GENOTROPIN
| Period | Revenue |
|---|---|
| Q2 2026 | $94.0M |
| Q1 2026 | $93.0M |
| Q3 2025 | $128.0M |
| Q2 2025 | $106.0M |
| Q1 2025 | $95.0M |
| Q3 2024 | $119.0M |
| Q2 2024 | $119.0M |
| Q1 2024 | $120.0M |
| Q4 2023 | $160.0M |
| Q3 2023 | $158.0M |
| Q2 2023 | $74.0M |
| Q1 2023 | $147.0M |
| Q4 2022 | $99.0M |
| Q3 2022 | $90.0M |
| Q2 2022 | $91.0M |
| Q1 2022 | $80.0M |
| Q4 2021 | $105.0M |
| Q3 2021 | $95.0M |
| Q2 2021 | $109.0M |
| Q1 2021 | $80.0M |
| Q4 2020 | $111.0M |
| Q3 2020 | $107.0M |
| Q2 2020 | $106.0M |
| Q1 2020 | $103.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (13)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| GENOTROPIN | SOMATROPIN | 0.4MG | For Injection |
| GENOTROPIN | SOMATROPIN | 12MG | For Injection |
| GENOTROPIN | SOMATROPIN | 0.2MG | For Injection |
| GENOTROPIN | SOMATROPIN | 5MG | For Injection |
| GENOTROPIN | SOMATROPIN | 0.6MG | For Injection |
| GENOTROPIN | SOMATROPIN | 1.5MG | For Injection |
| GENOTROPIN | SOMATROPIN | 1.2MG | For Injection |
| GENOTROPIN | SOMATROPIN | 0.8MG | For Injection |
| GENOTROPIN | SOMATROPIN | 1.4MG | For Injection |
| GENOTROPIN | SOMATROPIN | 2MG | For Injection |
| GENOTROPIN | SOMATROPIN | 1.6MG | For Injection |
| GENOTROPIN | SOMATROPIN | 1MG | For Injection |
| GENOTROPIN | SOMATROPIN | 1.8MG | For Injection |
13 products